Q-omics provides the consensus-scored SYT6 profile across patient tissues and cancer cell-line models. SYT6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, SYT6 is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, SYT6 RNA expression shows 15,705 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, KIRP, and THYM as cancer lineages where SYT6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYT6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYT6 survival associations across molecular data types. SYT6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYT6 RNA expression–survival associations across cancer types. High SYT6 expression shows unfavorable associations in UVM and LIHC, but favorable associations in UCS, ACC, LGG and SKCM. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify UCS as the clearest survival context for SYT6 RNA expression.
This table summarizes SYT6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for SYT6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYT6 shows lower tumor expression in KIRP, BRCA and COAD and higher tumor expression in LUAD, LUSC and LIHC. The KIRP box plot shows higher SYT6 RNA expression in normal versus tumor tissue (log2 FC = −1.006, t-test p < 0.001).
This table shows molecular features associated with SYT6 in patient tissues and cancer cell lines. In patient samples, SYT6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SYT6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
